Natural history of patients with low-level HIV viremia on antiretroviral therapy

AIDS Patient Care and STDs

Volumn 18, Issue 8, 2004, Pages 436-442

  Re III, Vincent Lo ^a   Gasink, Leanne ^a   Kostman, Jay R ^b   Leonard, Debra ^a   Gross, Robert ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; AGED; ARTICLE; CAUCASIAN; DISEASE COURSE; FEMALE; HAZARDS RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LOW LEVEL VIREMIA; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PREDICTION; RISK; RISK FACTOR; T LYMPHOCYTE SUBPOPULATION; VIREMIA; VIRUS LOAD;

EID: 4344701195     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/1087291041703692     Document Type: Article

References (19)

1. Collins ML, Irvine B, Tynerb D, et al. A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml. Nucleic Acids Res 1997;25:2979-2984.
2. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999;353:863-868.
3. + T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000;181:946-953.
4. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-87.
5. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002;288:222-235.
6. Panel on Clinical Practices for Treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. aidsinfo.nih.gov (Last accessed February 3, 2004).
7. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001;344:472-480.
8. Havlir D, Basett, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001;286:171-179.
9. Sklar PA, Ward DJ, Baker RK, et al. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS 2002;16:2035-2041.
10. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002;16:201-207.
11. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000;14:2857-2867.
12. Aleman S, Söderbärg K, Visco-Comandini U, et al. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 2002;16:1039-1044.
13. Giorgi JV, Cheng HL, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: The multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. Clin Immunol Immunopathol 1990;55: 173-186.
14. Collett D. Modeling Survival Data in Medical Research. London: Chapman and Hall, 1994.
15. Deeks SG. Durable HIV treatment benefit despite low-level viremia: Reassessing definitions of success or failure. JAMA 2001;286:224-226.
16. Ortiz GM, Nixon DF, Trkola A, et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999;104: R13-18.
17. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 2001;15:2109-2117.
18. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
19. Easterbrook PJ, Ives N, Waters A, et al. The natural history and clinical significance of intermittent viremia in patients with initial viral suppression to <400 copies/ml. AIDS 2002;16:1521-1527.